Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/29/2023 | $2.00 | Mkt Perform → Outperform | Barrington Research |
| 12/15/2022 | $3.00 | Buy | H.C. Wainwright |
| 1/24/2022 | Outperform → Market Perform | Barrington Research |
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
MIAMI, Nov. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the third quarter of 2024 and recent weeks include the following: Completed sale of select assets of BioReference Health to Labcorp for $237.5 million. OPKO completed the sale of BioReference Health's laboratory testing businesses focused on clinical diagnostics and women's health, excluding operations in New York and New Jersey, for $237.5 million. BioReference Health will continue to offer oncology and urology diagnostic services nationwide, as well as maintain its full operations in New Yor
AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the expansion of its co-marketing and distribution collaboration with BioReference Health, LLC ("BioReference"), a wholly-owned subsidiary of OPKO Health Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets. Under the terms of the expanded agreement, Aspira and BioReference will join forces to market Aspira's complete OvaSuite portfolio, including OvaWa
MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Thursday, November 7, 2024. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on November 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live opera
Barrington Research upgraded Opko Health from Mkt Perform to Outperform and set a new price target of $2.00
H.C. Wainwright initiated coverage of Opko Health with a rating of Buy and set a new price target of $3.00
Barrington Research downgraded OPKO Health from Outperform to Market Perform
WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera
NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (NASDAQ:TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company's board of directors and approved all other shareholder proposals during the company's first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Health (NASDAQ:OPK). Dr. Cohen brings 30 years of healthcare industry strategy and operating experience to Talkspace's board of directors. He succeeds Jeffrey Crowe as an independent Class I Director with a term expiring in 2025. Additionally, the Company's board appointed C
MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO's BioReference Laboratories. Ms. Stueland joins GeneDx from Invitae Corporation (NYSE:NVTA), where she served most recently as Chief Commercial Officer, establishing the corporate brand as Invitae evolved from a private company to a public entity with a market capitalization exceeding $6 billion. "We're thrilled to have Katherine lead the team at GeneDx, which has served clinicians and patients for more than two decades with novel and differentiated technologies for di
Opko Health, Inc. (NASDAQ:OPK) shares are trading higher Thursday after the company announced a $100 million share repurchase program. The Details: Opko said it expects to fund the repurchase program from existing cash and cash equivalents, and future cash flows. The company had approximately 697 million shares outstanding as of June 30, 2024, and the new authorization represents approximately 10.1% of shares outstanding at the current stock price. Read Next: Discover Reports Better-Than-Expected Q2 Results: Here’s The Details “We believe OPKO’s shares are significantly undervalued and offer an attractive investment opportunity. Buying back shares supports our conviction in OPKO’
U.S. stocks were higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Cintas Corporation (NASDAQ:CTAS) rose during Thursday's session after the company reported better-than-expected quarterly EPS and revenues. Cintas reported fourth-quarter earnings per share of $3.99, beating the street view of $3.80. The company registered quarterly revenues of $2.471 billion, beating the street view of $2.468 billion, according to data from Benzinga Pro. Cintas shares gained 5.3% to $758.25 on Thursday. Here are some other big stocks recording gains in today’s session. Chuy’s Holdings, Inc. (NASDAQ:CHUY) shares gained 47.6% to $37.29 after the company and Darde
10-Q - OPKO HEALTH, INC. (0000944809) (Filer)
8-K - OPKO HEALTH, INC. (0000944809) (Filer)
8-K - OPKO HEALTH, INC. (0000944809) (Filer)
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
4/A - OPKO HEALTH, INC. (0000944809) (Issuer)
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
MIAMI, Nov. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the third quarter of 2024 and recent weeks include the following: Completed sale of select assets of BioReference Health to Labcorp for $237.5 million. OPKO completed the sale of BioReference Health's laboratory testing businesses focused on clinical diagnostics and women's health, excluding operations in New York and New Jersey, for $237.5 million. BioReference Health will continue to offer oncology and urology diagnostic services nationwide, as well as maintain its full operations in New Yor
MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Thursday, November 7, 2024. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on November 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live opera
MIAMI, Aug. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second quarter and recent weeks include the following: Enrollment underway in the MDX2001 Phase 1 trial for the treatment of solid tumor cancers. MDX2001, a tetraspecific antibody, is designed to optimize T-cell function to stimulate tumor regression while minimizing the likelihood of antigen escape. This Phase 1 open-label trial is expected to enroll 45 cancer patients with a variety of solid tumors at six clinical trial sites, and to evaluate safety, tolerability, pharmacokinetics and early eviden
SC 13G/A - OPKO HEALTH, INC. (0000944809) (Subject)
SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)
SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)